Related Experiment Video
Updated: Feb 2, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous
Zhen Qu1, Mu-Fan Zhang1, Zhao Cui2
1Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
Background:
Anti-phospholipase A2 receptor (PLA2R) antibodies are specific to the diagnosis of primary membranous nephropathy (pMN). The prevalence of positive antibodies varies among different cohorts. Still there is discrepancy in regard to the association between antibody levels and clinical courses, and the prognostic value of antibodies to treatment responses and kidney outcomes.
Methods:
Three hundred fifty-nine consecutive kidney biopsy-proven pMN patients were enrolled. Anti-PLA2R antibodies were detected by immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA).
Results:
The positive rate of anti-PLA2R antibodies in pMN was 65.2% (234/359) by IFA and 56.3% (202/359) by ELISA. The antibody level presented positive correlation with urinary protein excretion (r = 0.164, p = 0.002). Detectable antibodies and a higher level of proteinuria were independent risk factors to no-remission after treatments (OR 3.15, p = 0.004; OR 1.11, p = 0.006) and were independent risk factors to no-spontaneous remission (OR 2.20, p = 0.011; OR 1.36, p < 0.001). A higher level of antibodies (hazard ratio 1.002, p = 0.019) was the independent risk factor to kidney dysfunction during follow-up. The antibodies turned negative in 42 out of 52 (80.8%) patients who achieved clinical remission, while they remained positive in all patients of the no-response category (p < 0.001).
Conclusion:
We documented correlations between anti-PLA2R antibody levels and clinical severity in this large Chinese pMN cohort. Antibody positivity and higher antibody level might predict treatment responses and kidney outcomes of pMN.
Insights
Anti-phospholipase A2 receptor (PLA2R) antibodies are key in diagnosing primary membranous nephropathy (pMN). Higher PLA2R antibody levels correlate with worse outcomes and predict treatment response and kidney health in pMN patients.
Area of Science:
- Nephrology
- Immunology
- Clinical Diagnostics
Background:
- Anti-phospholipase A2 receptor (PLA2R) antibodies are diagnostic markers for primary membranous nephropathy (pMN).
- Prevalence and clinical significance of these antibodies vary across patient cohorts.
- The prognostic value of antibody levels for treatment response and kidney outcomes remains debated.
Purpose of the Study:
- To investigate the association between anti-PLA2R antibody levels and clinical severity in a Chinese pMN cohort.
- To evaluate the predictive value of anti-PLA2R antibodies for treatment response and kidney outcomes in pMN.
- To establish correlations between antibody levels and disease progression.
Main Methods:
- Enrolled 359 kidney biopsy-proven pMN patients.
- Detected anti-PLA2R antibodies using immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA).
- Analyzed correlations between antibody levels, proteinuria, treatment response, and kidney outcomes during follow-up.
Main Results:
- Anti-PLA2R antibody positivity rates were 65.2% (IFA) and 56.3% (ELISA).
- Higher antibody levels correlated with increased urinary protein excretion and predicted poor treatment response and spontaneous remission.
- Elevated antibody levels were an independent risk factor for kidney dysfunction during follow-up.
Conclusions:
- This study documents significant correlations between anti-PLA2R antibody levels and clinical severity in a large Chinese pMN cohort.
- Antibody positivity and higher levels may predict treatment responses and kidney outcomes in pMN.
- Anti-PLA2R antibody levels serve as a valuable prognostic marker in pMN management.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
Predicting Reaction Outcomes
Types of Receptors: Internal Receptors
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
Types of Receptors: Cell Surface Receptors
Types of Membrane Protrusions
The microvilli, an example of stable protrusions, are finger-like projections...
Internal Receptors
Types of Hormones